RAPGEF3 and cancer: While inhibition of cAMP synthesis or PKA/EPAC can inhibit some types of cancer and stimulate anticancer immunity, cAMP-elevating agents such as the adenylate cyclase agonist forskolin and the cAMP analog 8-Br-cAMP also emerge as potential cancer therapeutics, especially when combined with other anticancer agents.